RxDoctor Payments Data

Grant Lewis, MD

Hematology & Oncology · Savannah, GANPI 1215009287

Payments from drug & device makers

$177,098in general payments, 2019–2025

Across 726 payments — averaging $243.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$165K
  • Merck$1K
  • Novartis$1K
  • Pfizer$796
  • AstraZeneca$752
  • Amgen$609
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,89398%
  • Education$2322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.53$164,633
Merck70$1,349
Novartis77$1,342
Pfizer51$796
AstraZeneca(2 entities)42$752
Amgen35$609
Gilead(2 entities)31$576
Johnson & Johnson(2 entities)30$565
Genentech USA, Inc.31$524
Eisai Inc.20$382
Daiichi Sankyo Inc.17$356
AbbVie18$324
Seagen Inc.17$294
Bayer16$293
Astellas Pharma US Inc11$291
Bristol Myers Squibb14$277
Incyte Corporation15$262
Regeneron Healthcare Solutions, Inc.13$248
Sanofi9$228
GSK11$209
Array Biopharma Inc11$185
Exelixis Inc.10$167
Puma Biotechnology, Inc.9$165
Lilly USA, LLC8$149
Takeda Pharmaceuticals U.S.A., Inc.7$149
Pharmacosmos Therapeutics Inc.6$131
Taiho Oncology, Inc.5$122
Acrotech Biopharma Inc.7$119
Beigene USA, Inc.7$115
Ipsen Biopharmaceuticals, Inc5$101
Apellis Pharmaceuticals, Inc.3$100
Foundation Medicine, Inc.1$92
Pharmacyclics LLC, An Abbvie Company5$84
Karyopharm Therapeutics Inc.4$72
Beone Medicines USA, Inc.3$71
EMD Serono, Inc.3$62
Sobi, Inc3$62
Geron Corporation3$61
AVEO Pharmaceuticals, Inc.3$53
Servier Pharmaceuticals LLC3$52
Boehringer Ingelheim2$40
Mirati Therapeutics, Inc.2$38
Mylan Institutional Inc.2$38
Sanofi-aventis U.S. LLC2$37
AMAG Pharmaceuticals, Inc.2$37
G1 Therapeutics, Inc.2$36
Kyowa Kirin, Inc.2$35
Rigel Pharmaceuticals, Inc.1$33
Recordati_rare_diseases_inc.2$33
Sun Pharmaceutical Industries Inc.2$31
Jazz Pharmaceuticals Inc.2$31
ADC Therapeutics America, Inc.2$30
Lexicon Pharmaceuticals, Inc.2$27
Alnylam Pharmaceuticals Inc.1$25
Deciphera Pharmaceuticals Inc.1$20
Emmaus Medical, Inc.1$19
Octapharma USA, Inc.1$19
Agios Pharmaceuticals, Inc.1$18
CTI Biopharma Corp.1$17
Heron Therapeutics, Inc.1$16

How this compares

$177,098 in reported general payments places this provider in the 80th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$255,848
Medicare patients
638
Services billed
14,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide55$1,094,309
PomalystPomalidomide31$716,611
Lenalidomide45$639,514
IbrancePalbociclib25$404,679
ImbruvicaIbrutinib16$326,082
XtandiEnzalutamide21$292,609
BrukinsaZanubrutinib19$270,625
TagrissoOsimertinib Mesylate15$249,344
CalquenceAcalabrutinib Maleate13$187,110
JakafiRuxolitinib Phosphate13$135,676
VerzenioAbemaciclib15$133,103
Imatinib Mesylate27$63,494
EliquisApixaban23$38,160
Deferasirox16$5,822
Exemestane18$3,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$277$1,094,30955 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$164,633$716,61131 claims
PfizerIbrance, Eliquis$796$442,83948 claims
AstraZenecaTagrisso, Calquence$752$436,45428 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$84$326,08216 claims
Astellas Pharma US IncXtandi$291$292,60921 claims
Beigene USA, Inc.Brukinsa$115$270,62519 claims
Incyte CorporationJakafi$262$135,67613 claims
Lilly USA, LLCVerzenio$149$133,10315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →